multiple system atrophy
multiple system atrophy
Explore linked clinical trials. Standard reference: MONDO:000780390 results · Page 1 of 4
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France | autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy | Enrolling by invitation | Phase 2 | 2026-10-09 | NCT07729852 | |
| An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy | autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy | Recruiting | Phase 2 | 2026-10-09 | NCT07197866 | |
| A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy | autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy | Active, not recruiting | Phase 2 | 2026-10-09 | NCT06568237 | |
| Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial | Neurologic Manifestations, Ocular Motility Disorders, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, cranial nerve neuropathy, eye disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, parkinsonian disorder, primary dysautonomia, synucleinopathy, tauopathy | Recruiting | Phase 1 / Phase 2 | 2026-10-07 | NCT07863180 | |
| A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy | autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy | Active, not recruiting | Phase 2 | 2026-10-06 | NCT05923866 | |
| VisMemoPD Protocol: an Observational Pilot Study on Spatial and Topographical Memory in Patients With Parkinson's Disease and Parkinsonism | Cognition Disorders, Cognitive Dysfunction, Mild Cognitive Impairment, Neurologic Manifestations, Ocular Motility Disorders, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, cranial nerve neuropathy, eye disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, parkinsonian disorder, primary dysautonomia, progressive supranuclear palsy, psychiatric disorder, synucleinopathy, tauopathy | Not yet recruiting | Not stated | 2026-09-18 | NCT07827963 | |
| Neurodegenerative Diseases Registry | Neurologic Manifestations, Ocular Motility Disorders, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, cranial nerve neuropathy, eye disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, parkinsonian disorder, primary dysautonomia, progressive supranuclear palsy, synucleinopathy, tauopathy | Recruiting | Not stated | 2026-09-18 | NCT04472130 | |
| A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P) | Parkinson disease, autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, parkinsonian disorder, primary dysautonomia, synucleinopathy | Not yet recruiting | Phase 3 | 2026-09-17 | NCT07825402 | |
| The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar Type | autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy | Recruiting | Early phase 1 | 2026-09-09 | NCT07514923 | |
| Expansion Study of ALT001 in Patients With Multiple System Atrophy | autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy | Recruiting | Early phase 1 | 2026-09-09 | NCT07476352 | |
| Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH) | Lewy body dementia, Neurologic Manifestations, Ocular Motility Disorders, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, corticobasal degeneration disorder, cranial nerve neuropathy, dementia, eye disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, parkinsonian disorder, primary dysautonomia, psychiatric disorder, synucleinopathy, tauopathy | Recruiting | Not stated | 2026-09-08 | NCT07805967 | |
| Neurodegenerative Diseases Progression Markers (MARKERS-NDD) | Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Frontotemporal Lobar Degeneration, Lewy body dementia, Neurologic Manifestations, Nutritional and Metabolic Diseases, Ocular Motility Disorders, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, amyotrophic lateral sclerosis, autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, corticobasal degeneration disorder, cranial nerve neuropathy, dementia, eye disorder, hereditary disease, inherited neurodegenerative disorder, iron metabolism disease, iron poisoning, metabolic disease, motor neuron disorder, movement disorder, multiple system atrophy, nervous system disorder, neuroaxonal dystrophy, neurodegeneration with brain iron accumulation, neurodegenerative disease, neuromuscular disease, ophthalmoplegia, palsy, pantothenate kinase-associated neurodegeneration, parkinsonian disorder, primary dysautonomia, proteostasis deficiencies, psychiatric disorder, spinal cord disorder, synucleinopathy, tauopathy | Recruiting | Not stated | 2026-09-02 | NCT06596746 | |
| A Study to Evaluate Satety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With PD and Patients With MSA | Parkinson disease, autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, parkinsonian disorder, primary dysautonomia, synucleinopathy | Recruiting | Phase 1 | 2026-09-01 | NCT07604116 | |
| Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies | Nutritional and Metabolic Diseases, Parkinson disease, autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, metabolic disease, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, parkinsonian disorder, primary dysautonomia, proteostasis deficiencies, synucleinopathy | Recruiting | Phase 1 | 2026-08-31 | NCT06683365 | |
| Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease | Lewy body dementia, Parkinson disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autonomic nervous system disorder, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cognitive disorder, dementia, disease, familial cylindromatosis, hypotensive disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, parkinsonian disorder, primary dysautonomia, psychiatric disorder, synucleinopathy, vascular disorder | Active, not recruiting | Not stated | 2026-08-28 | NCT06846658 | |
| A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy | autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy | Not yet recruiting | Phase 1 | 2026-08-19 | NCT07774585 | |
| A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy | autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy | Active, not recruiting | Phase 2 | 2026-08-19 | NCT06848231 | |
| Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study | Alzheimer disease, Arterial Occlusive Diseases, Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Frontotemporal Lobar Degeneration, Huntington disease, Leukoencephalopathies, Lewy body dementia, Neurologic Manifestations, Nutritional and Metabolic Diseases, Ocular Motility Disorders, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, amyotrophic lateral sclerosis, arteriosclerosis disorder, autonomic nervous system disorder, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, choreatic disease, cognitive disorder, corticobasal degeneration disorder, cranial nerve neuropathy, dementia, eye disorder, frontotemporal dementia, hereditary disease, inherited neurodegenerative disorder, intracranial arterial disease, intracranial arteriosclerosis, metabolic disease, motor neuron disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, neuromuscular disease, ophthalmoplegia, palsy, parkinsonian disorder, primary dysautonomia, progressive supranuclear palsy, proteostasis deficiencies, psychiatric disorder, spinal cord disorder, synucleinopathy, tauopathy, vascular dementia, vascular disorder | Active, not recruiting | Not stated | 2026-08-10 | NCT06209515 | |
| Test-retest Trial With [11C]MODAG-005 in PD or MSA and AMHC - Pilot Phase | Nerve Degeneration, Parkinson disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autonomic nervous system disorder, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, hypotensive disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, parkinsonian disorder, primary dysautonomia, synucleinopathy, vascular disorder | Recruiting | Early phase 1 | 2026-07-31 | NCT07640542 | |
| Automated Imaging Differentiation of Parkinsonism | Neurologic Manifestations, Ocular Motility Disorders, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, cranial nerve neuropathy, eye disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, parkinsonian disorder, primary dysautonomia, progressive supranuclear palsy, synucleinopathy, tauopathy | Active, not recruiting | Not stated | 2026-07-31 | NCT05913687 | |
| Remote Monitoring in Progressive Supranuclear Palsy (PSP) | Neurologic Manifestations, Ocular Motility Disorders, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, autonomic nervous system disorder, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cranial nerve neuropathy, eye disorder, hypotensive disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, parkinsonian disorder, primary dysautonomia, progressive supranuclear palsy, synucleinopathy, tauopathy, vascular disorder | Not yet recruiting | Not stated | 2026-07-29 | NCT04753320 | |
| A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) | autonomic nervous system disorder, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, primary dysautonomia, synucleinopathy | Active, not recruiting | Phase 3 | 2026-07-14 | NCT06706622 | |
| Gait Analysis in Neurological Disease | Atypical Parkinson Disease, Cognition Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Gait Disorders, Neurologic, Gait, Frontal, Huntington disease, Neurologic Manifestations, Ocular Motility Disorders, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Spinocerebellar Ataxias, Spinocerebellar Degenerations, atactic disorder, non-human animal, autonomic nervous system disorder, autosomal dominant Parkinson disease 1, basal ganglia disorder, brain disorder, central nervous system disorder, cerebellar ataxia, cerebellar disorder, choreatic disease, cognitive disorder, corticobasal degeneration disorder, cranial nerve neuropathy, dementia, eye disorder, hereditary disease, inherited neurodegenerative disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, parkinsonian disorder, primary dysautonomia, progressive supranuclear palsy, psychiatric disorder, spinal cord disorder, synucleinopathy, tauopathy | Active, not recruiting | Not stated | 2026-07-08 | NCT02994719 | |
| Epidural Electrical Stimulation to Support Hemodynamic Management in Individuals With Parkinson's Disease | Hypotension, Orthostatic, Multiple system atrophy (MSA) with orthostatic hypotension, Parkinson disease, autonomic nervous system disorder, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, hypotensive disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, orthostatic intolerance, parkinsonian disorder, primary dysautonomia, pure autonomic failure, synucleinopathy, vascular disorder | Recruiting | Not applicable | 2026-07-07 | NCT06920134 | |
| Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms | Hypotension, Orthostatic, autonomic nervous system disorder, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, hypotensive disorder, movement disorder, multiple system atrophy, nervous system disorder, neurodegenerative disease, orthostatic intolerance, parkinsonian disorder, primary dysautonomia, pure autonomic failure, synucleinopathy, vascular disorder | Recruiting | Not applicable | 2026-07-02 | NCT04782830 |